Getting Started

Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date	Manual Section	Add/Remove/Modify	Description
2/20/2026	4100: Cellular Therapy Essential Data Follow-Up	Add	Version 10 of the Cellular Therapy Essential Data Pre- Infusion section of the Forms Instructions Manual released. Version 10 corresponds to revision 10 of the Form 4100.
2/20/2026	2146: Fungal Infection Post-Infusion Data	Modify	Version 3 of the 2146: Fungal Infection Post-Infusion Data section of the Forms Instructions Manual released. Version 3 corresponds to revision 5 of the Form 2146.
2/20/2026	2046: Fungal Infection Pre-Infusion Data	Modify	Version 3 of the 2046: Fungal Infection Pre-Infusion Data section of the Forms Instructions Manual released. Version 3 corresponds to revision 6 of the Form 2046.
1/23/2026	2100:Post-Infusion Follow-Up Form	Modify	Updated the Combined Follow Up blue box in Q384: Combined Follow Up and Functional Status: In scenarios where a cellular therapy is given after a HCT and this form is being completed based on the subsequent cellular therapy, these questions do not apply and are disabled and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Organ Function blue box added to Q250 – 377: Combined Follow Up and Organ Function: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Current GVHD Status blue box added to Q205: Combined Follow Up and Current GVHD Status: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Chronic GVHD blue box added in Q135: Combined Follow Up and Chronic GVHD: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, chronic GVHD will always be reported on the Post-Infusion Follow-Up (2100) Form and is disabled on the Cellular Therapy Essential Data Follow- Up (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Acute GVHD blue box added in Q86: Combined Follow Up and Acute GVHD: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, acute GVHD will always be reported on the Post-Infusion Follow-Up (2100) Form and is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Immune Reconstitution blue box added: Combined Follow Up and Immune Reconstitution: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Updated Combined Follow Up blue box in Q30: Combined Follow-Up: In scenarios where a cellular therapy is given after a HCT and this form is being completed based on the subsequent cellular therapy, these questions do not apply and are disabled if there is a corresponding Post-Cellular Therapy Follow-Up 4101) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Growth Factor and Cytokine Therapy blue box added to Q21: Combined Follow Up and Growth Factor and Cytokine Therapy: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Survival Status blue box added to Q2: Combined Follow Up and Survival Status: When both HCT and cell therapy forms are being completed, the survival status on the Post-Infusion Follow-Up (2100) Form should match the corresponding the Post-CTED (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Subsequent Infusion blue box added to Q3: Combined Follow Up and Subsequent Infusion: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, subsequent infusions are reported on the Post-Infusion Follow-Up (2100) Form and the question is disabled on the Cellular Therapy Essential Data Follow- Up (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Contact Date blue box added to Q1: Combined Follow Up and Contact Date: When both HCT and cell therapy forms are being completed, the date of contact on the Post-Infusion Follow-Up (2100) Form should match the corresponding the Post-CTED (4100) Form.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and FMT blue box added to Q92: Combined Follow Up and FMT: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Liver Toxicity Prophylaxis blue box added in Q34: Combined Follow-Up and Liver Toxicity Prophylaxis: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and VOD / SOS blue box added in Q37: Combined Follow-Up and VOD / SOS: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Modify	Combined Follow Up blue box updated in Q9: Combined Follow Up GVHD: In scenarios where a CT was given after an HCT and this form is now being completed based on the subsequent CT date, GVHD will always be reported on the Post-TED (2450) Form and is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form. In scenarios where both HCT and cell therapy forms are being completed, GHVD questions are disabled on the Cellular Therapy Essential Data Follow-Up (4100) form and should be answered on the Post-TED (2450).
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Secondary Graft Failure blue box added in Q6: Combined Follow Up and Secondary Graft Failure: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, Did secondary graft failure occur? still applies and should be answered.
1/23/2026	2450: Post-TED	Modify	Combined Follow Up blue box updated in Q3: Combined Follow Up and Subsequent Infusion: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, subsequent infusions are always reported on the Post-TED (2450) Form and the question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form. When both HCT and cell therapy forms are being completed, the subsequent infusion question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) form and should be answered on the Post-TED (2450).
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Survival Status blue box added to Q2: Combined Follow Up and Survival Status: When both HCT and cell therapy forms are being completed, the survival status on the Post-TED (2450) Form should match the corresponding Post-CTED (4100) Form. If death occurred in the reporting period, Death must be reported as the survival status on both the HCT and cellular therapy forms. Two Recipient Death (2900) Forms will come due; however, only one form needs to be completed. Contact CIBMTR Center Support to remove the duplicate.
1/23/22026	3505: Transfusion	Add	Added to the intro when this form will come due: This form will come due for those recipients enrolled onto CIBMTR study CS22-24 (Zyntelgo®). This is a post marketing prospective, multicenter, observational, long-term safety and effectiveness registry study of recipients with beta-thalassemia treated with Betibeglogene Autotemcel (Zynteglo®) and CIBMTR study CS20-55 (Casgevy®): Long-term registry-based study of patients with transfusion-dependent β-thalassemia (TDT) or sickle cell disease (SCD) treated with exagamglogene autotemcel (CasgevyTM).
1/23/2026	2199: Donor Lymphocyte Infusion	Modify	Updated the Partial Response and Complete Response criteria for suboptimal donor chimerism in Table 1 (Q38): PR: Increase in CD33 and or CD3 chimerism but not 95% donor chimerism; CR: > 95% donor chimerism in CD33 and or CD3
1/23/2026	2400: Pre-TED	Add	Dosing Weight Disabled blue note box added to Q143: Dosing Weight Disabled: With the Winter 2026 release (January 23, 2026), the Dosing weight used for preparative regimen orders question is disabled..
1/23/2026	Appendix J: Reporting Comorbidities	Modify	Replaced To Correct and Uncorrected DLCO blue note box with Dinakara Equation blue note box: To correct an uncorrected DLCO: corrected DLCO= uncorrected DLCO/(0.06965*hemoglobin) where hemoglobin is measured in g/dL Dinakara Equation: Use the following equation to adjust and uncorrected DLCO where the hemoglobin is the closest value to the PFT assessment date (measured in g/dL): corrected DLCO= uncorrected DLCO/(0.06965*hemoglobin)
1/23/2026	Appendix J: Reporting Comorbidities	Modify	Clarified when the Dinakara equation shoud be used: For instances in which the pulmonary function testing report does not correct diffusing capacity of carbon monoxide for hemoglobin, use the Dinakara equation to correct. When determining if a pulmonary comorbidity is present, the Dinakara equation for calculating the adjusted DLCO must be used to assess if the criteria for the pulmonary comorbidity is met. If it is unclear if the PFT utilizes the Dinakara equation, seek clinician / lab clarification. If the PFT does not use the Dinakara equation when determining the adjusted DLCO, calculate the adjusted DLCO using the Dinakara and use the calculated value when determining if the pulmonary comorbidity criteria is met.
1/23/2026	Appendix J: Reporting Comorbidities	Add	Adjusted DLCO Requirements red warning box added: Adjusted DLCO Requirements: As of the Winter 2026 quarterly release (January 23, 2026), the Dinakara equation for calculating the adjusted DLCO is required to be used when assessing if the criteria for the pulmonary comorbidity is met. If the PFT does not use the Dinakara equation or it is unknown if used, calculate the adjusted DLCO using the equation provided below.
1/23/2026	Appendix J: Reporting Comorbidities	Add	What to Report table updated to clarify the Dinakara equation is required to be used when determining if a pulmonary (moderate or severe) comorbidity is present). Adjusted DLCO 66 – 80% / < 65%, using the Dinakara equation (See Adjusted DLCO Requirements red warning box below)
1/23/2026	Appendix J: Reporting Comorbidities	Modify	Reformatted the instructions provided outside of What to Report and What Not to Report tables for better instruction flow.
1/23/2026	2450: Post-TED	Add	Non-US Centers and Platelet Recovery red warning box added: Non-US Centers and Platelet Recovery: Prior to the Fall 2025 release (October 24, 2025), the platelet recovery questions were optional for non-US centers. However, as of October 24, 2025, this question is now required to be answered for all centers. If completing the Post-TED (2450) Form for a six-month or annual reporting period and the previously completed Post-TED (2450) Form did not require the platelet question to be answered, leave the Was an initial platelet count > 20 × 109/L achieved question blank and override the error as ‘verified correct.’
1/23/2026	2100:Post-Infusion Follow-Up Form	Modify	Updated example 3 in Q383: Example 3: A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discreet lesion. Report Yes, there was a new malignancy on the Post-HCT Follow-Up (2100) and a single Subsequent Neoplasms (3500) form will come due to report one of the basal cell malignancies. Create a second Subsequent Neoplasms (3500) form to report the other basal cell malignancy as these are discreet episodes. A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. In the two-year reporting period, the recipient was diagnosed with an additional basal cell skin cancer on the arm. For the one-year reporting period, report Yes, there was a new malignancy on the Post-Infusion Follow-Up (2100) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 2 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). For the two-year reporting period, report Yes, there was a new malignancy on the Post-Infusion Follow-Up (2100) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 1 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500).
1/23/2026	2100:Post-Infusion Follow-Up Form	Modify	Replaced Recurrent Skin Cancers blue note box with Recurrent Non-Melanoma Skin Cancers blue note box in Q383: Recurrent Skin Cancers: For most malignancies, do not report recurrence, progression, or transformation of the recipient’s primary disease (disease for which the transplant was performed) or relapse of a prior malignancy in the “New Malignancy” section. However, in the case of a basal cell or squamous cell skin cancer, report each discreet episode as a new malignancy. See Example 3 below for additional information. Recurrent Non-Melanoma Skin Cancers: If there is a recurrence of non-melanoma skin cancers in the reporting period, select Yes for Did a new malignancy, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the HCT or cellular therapy was performed and a single Subsequent Neoplasms (3500) will come due, allowing the total number of non-melanoma skin cancer lesions diagnosed during the reporting period to be reported. If additional non-melanoma skin cancer lesions are diagnosed in the reporting period, update the reported total number of non-melanoma skin cancer lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). Do not create separate Subsequent Neoplasms (3500) forms for each discrete lesion diagnosed in the reporting period. If a non-melanoma skin cancer is diagnosed again in a future reporting period, repeat the process for that reporting period.
1/23/2026	2450: Post-TED	Modify	Updated example 3 in Q39: Example 3: A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discreet lesion. Report Yes, there was a new malignancy on the Post-TED (2450) Form, and a single Subsequent Neoplasms (3500) Form will come due to report one of the basal cell malignancies. Create a second Subsequent Neoplasms (3500) form to report the other basal cell malignancy as these are discreet episodes. A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. In the two-year reporting period, the recipient was diagnosed with an additional basal cell skin cancer on the arm. For the one-year reporting period, report Yes, there was a new malignancy on the Post-TED (2450) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 2 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). For the two-year reporting period, report Yes, there was a new malignancy on the Post-TED (2450) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 1 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500).
1/23/2026	2450: Post-TED	Modify	Replaced Recurrent Skin Cancers blue note box with Recurrent Non-Melanoma Skin Cancers blue note box in Q39: Recurrent Skin Cancers: For most malignancies, do not report recurrence, progression or transformation of the recipient’s primary disease (disease for which the infusion was performed) or relapse of a prior malignancy in the “New Malignancy” section. However, for recurrent skin cancers, each discrete lesion should be reported. For example, in the six-month reporting period, a recipient was diagnosed with basal cell skin cancer on the neck four months post-infusion and in the one-year reporting, the recipient was diagnosed with another basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. These discrete episodes should be reported as a ‘new malignancy’ on the Post-TED (2450) Forms. Recurrent Non-Melanoma Skin Cancers: If there is a recurrence of non-melanoma skin cancers in the reporting period, select Yes for Did a new malignancy, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the HCT or cellular therapy was performed and a single Subsequent Neoplasms (3500) will come due, allowing the total number of non-melanoma skin cancer lesions diagnosed during the reporting period to be reported. If additional non-melanoma skin cancer lesions are diagnosed in the reporting period, update the reported total number of non-melanoma skin cancer lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). Do not create separate Subsequent Neoplasms (3500) forms for each discrete lesion diagnosed in the reporting period. If a non-melanoma skin cancer is diagnosed again in a future reporting period, repeat the process for that reporting period.
1/23/2026	2012: CML Pre-Infusion Data	Modify	Corrected time point for reporting molecular results in Q148 – 149: If testing for molecular markers was performed at diagnosis the time of best response, report “yes” and indicate the sample collection date in question 149. If the exact date is not known, use the process described for reporting partial or unknown dates in General Instructions, General Guidelines for Completing Forms. If no molecular marker testing was performed or it is unknown if testing was done, report “no” or “unknown” respectively and go to question 179.
1/23/2026	2450: Post-TED	Modify	Updated Chimerism Studies blue info box above Q40: This section relates to chimerism studies from allogeneic HCTs using cord blood units, or for allogeneic HCT recipients whose primary disease is beta thalassemia or sickle cell disease only a non-malignant. If this was an autologous HCT, an allogeneic HCT using a bone marrow or PBSC product, and / or allogeneic HCT recipient whose primary disease for transplant was not beta thalassemia or sickle cell disease a non-malignant disease, continue to the disease assessment section.
1/23/2026	CML Response Criteria	Modify	Chronic phase and CR criteria updated: Chronic Phase: Characterized by relatively few blasts (<10%) present in the blood and or bone marrow. Symptoms are often not present. The chronic phase may last several months to years, depending on the recipient and the treatment they receive. ; CR: Hematologic complete remission is defined as a treatment response where all of the following criteria are met: White blood count is < 10 × 109/L, without immature granulocytes and with < 5% basophils Platelet count < 450 × 109/L Non-palpable spleen
1/23/2026	2402: Disease Classification	Add	Clarified how to report germ cell and non-germ cell tumors of the ovaries and testes in Q559 – 560: CIBMTR captures the classification for solid tumors based on the World Health Organization (WHO) 2022 classification. Indicate the solid tumor disease classification at the time of diagnosis. Germ cell tumors that originate in the ovary or testes should be reported as ovarian or testicular, respectively. If the subtype is not listed, report as Other solid tumor and specify the reported malignancy. Report germ cell tumors originating in the ovaries or testes as Germ cell tumor, gonadal. Report ovarian non-germ cell tumors as Ovarian (epithelial) and testicular non-germ cell tumors as Testicular. If a certain disease becomes a common indication for infusion, the CIBMTR will add the disease as a separate category.
1/23/2026	2450: Post-TED	Add	Clarified how to report the initial therapy start date in Q90 when treatment was started prior to the addition of this question: Indicate if the initial therapy given for reasons other than decrease / loss of chimerism, consolidation therapy, MRD, relapse, persistent, or progressive disease was reported in a previous reporting period. The intent of this question is to capture the start date of the first maintenance therapy administered. If the initial start date was not reported in a prior reporting period, select No and report the initial therapy start date. If maintenance therapy was started, stopped, and restarted, report the date when the therapy first began. If a maintenance therapy was started and then switched to a different maintenance therapy, report the start date of the first maintenance therapy. If initial therapy was started in a previous reporting period and the prior Post-TED (2450) Form did not collect if the initial therapy date was previously reported, select Yes. The therapy start date is not captured for recipients who started their initial therapy prior to the addition of this question. If exact date is not known, refer to General Instructions, General Guidelines for Completing Forms for information about reporting partial or unknown dates.
1/23/2026	2451: Chimerism Essential Data	Add	Reporting the Same Cell Type Results Assessed by Different Samples and Reporting Multiple Other Cell Types blue boxes added above Q2 – 3.
1/23/2026	2400: Pre-TED	Add	Clarified Q12 intent: The intent of this question is to determine care access, regardless of the language spoken. Indicate if the recipient (or their parent, guardian, or legally authorized representative) requires interpreter services for any aspect of care, including verbal communication, reading, or other forms of assistance. Interpreters may include professional interpreters, family members, friends, or other individual who help facilitate communication.
1/23/2026	2450: Post-TED	Modify	Typo in Q32 – 33 instructions for reporting GVHD steroid treatment correct: These questions are intended to capture if the recipient was still receiving systemic steroids (steroid dose < 10 mg / day for adults, < < 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) and non-steroid immunosuppressive agents for GVHD on the contact date. Indicate if the recipient was still taking systemic steroids (steroid dose < 10 mg / day for adults, < < 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) and non-steroid immunosuppressive agents on the contact date. Review the GVHD Reporting Instruction Overview for reporting instructions to these questions.
1/23/2026	JMML Response Criteria	Add	JMML Disease Status Response Options red warning box and Table 1. JMML Disease Status Response Options table added

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.